Previous close | 332.16 |
Open | 327.06 |
Bid | 307.01 x 800 |
Ask | 306.01 x 800 |
Day's range | 307.00 - 328.17 |
52-week range | 302.61 - 659.45 |
Volume | |
Avg. volume | 800,803 |
Market cap | 29.899B |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | 58.18 |
EPS (TTM) | 5.30 |
Earnings date | 27 Apr 2022 - 02 May 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 546.94 |
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of DexCom, Inc...
Let's look at two top stocks that have performed worse than the broader market this year: DexCom (NASDAQ: DXCM) and Microsoft (NASDAQ: MSFT). Shares of medical devices specialist DexCom have dropped by 39% year to date. DexCom's own G6 CGM system continues to be highly successful.
SAN DIEGO, May 10, 2022--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences: